Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamphetamine Sulfate

Takeda said Thursday it has ended work on several early- and mid-stage drug candidates, adding that its second quarter sales took a hit from “generic erosion” and “unfavourable” exchange rates. The Japanese drugmaker nixed an AstraZeneca-partnered candidate for multiple system atrophy called TAK-341 after it missed the primary and secondary endpoints in a Phase 2 trial, according to a financial report . It also terminated two Phase 1 programs for narcolepsy (TAK-925) and acute myeloid leukemia (TAK-012), citing “strategic considerations.” Takeda obtained TAK-012 as part of its 2021 acquisition of GammaDelta Therapeutics. The cell therapy candidate was one of several programs impacted by Takeda’s broader decision to end all work on cell therapies earlier this month. Elsewhere, the company dropped a MASH asset called TAK-647 as part of a “portfolio prioritization.” The drug was originally developed by Pfizer, which licensed it out to Shire in 2016. Takeda then acquired Shire for $62 billion in 2019. Takeda has been trimming its pipeline as part of a multi-year rehaul designed in part to focus its resources on six late-stage programs that it believes could deliver billions of dollars in sales. These include its narcolepsy candidate, oxeporexton, which had a positive Phase 3 readout in September. The company has also been bulking out its late-stage pipeline through deals, licensing a Phase 3 ADC and a Phase 3-ready bispecific from Innovent for $1.2 billion upfront earlier this month. Meanwhile, Takeda’s Q2 revenues, from July to September, slid about 4% from the same time last year to JPY 2.2 trillion ($14.3 billion). The drop was largely due to weaker sales in the company’s neuroscience franchise, driven by generic competition for its ADHD medicine Vyvanse in the US. Vyvanse sales plummeted about 46% to $692.6 million, while its other ADHD drug Adderall XR declined 33% to $68.8 million. Takeda’s major depressive disorder treatment Trintellix was separately impacted by the redesign of Medicare Part D, with sales down 7% to $370.2 million.

Clinicians at Ascendant warn that long-term stimulant use can leave people drained, anxious, and vulnerable to depression. NEW YORK, NY, UNITED STATES, September 3, 2025 / EINPresswire.com / -- Ascendant Intensive Outpatient Program NYC , a boutique addiction treatment center in Midtown Manhattan, is calling attention to the growing dangers of stimulant misuse—from prescription drugs like Adderall ® to street drugs such as methamphetamine and crack cocaine. These substances are often prescribed or used with the intent to help, yet misuse has fueled a steady rise in dependence and treatment admissions nationwide. Prescription stimulants can be effective when taken as directed, particularly for conditions like ADHD. Still, misuse is common. Adderall ® , for instance, is sometimes taken without a prescription by students or professionals chasing sharper focus or more energy. Methamphetamine, though available in limited medical use under the name Desoxyn ® , is more often found in illicit forms that are unpredictable and highly addictive. Crack cocaine, a potent stimulant with a notorious reputation, continues to circulate on the streets under names like “snow” or “blow.” Misuse often goes beyond simply taking too many pills. Crushing and snorting Adderall ® , injecting meth, or smoking crack are all methods that intensify the high but dramatically increase health risks. Overdose, seizures, heart problems, and long-term cognitive decline are not rare outcomes. Federal data show that in 2021, more than 3.7 million people in the U.S. misused prescription stimulants, and cocaine was linked to nearly two out of five overdose deaths in 2016. Clinicians at Ascendant warn that long-term stimulant use can leave people drained, anxious, and vulnerable to depression. Withdrawal is another hurdle: cravings, paranoia, and mood swings make quitting extremely difficult without medical oversight. To support individuals and families, Ascendant NYC provides: 24/7 medical detox to manage withdrawal safely. Residential and outpatient programs for different stages of recovery. Therapies such as Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), and trauma-focused care. Wellness services including mindfulness, art therapy, and peer counseling for lasting support. The center emphasizes that stimulant misuse doesn’t follow one profile. High school students, college athletes, busy executives, or individuals with existing mental health struggles may all be at risk. Recognizing early warning signs—such as erratic sleep, paranoia, or “doctor shopping”—can open the door to timely treatment. About Ascendant NYC Ascendant NYC is a boutique addiction treatment center located in Midtown Manhattan, offering detox, residential, and outpatient programs. Since 2018, the center has provided compassionate, evidence-based care for individuals struggling with substance use. With an emphasis on safety, privacy, and individualized treatment, Ascendant helps clients rebuild their lives with the tools and support needed for long-term recovery. Admission Office Ascendant Intensive Outpatient Program NYC +1 (917) 924-4456 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.